
Bluenote is an enterprise AI platform for life sciences that automates regulatory and clinical documentation with full source traceability.
Bluenote brings life-saving therapies to patients sooner by accelerating regulatory submissions by 50 to 75 percent with advanced AI for life sciences. The platform is trusted by large pharma, medical device, diagnostics, CRO and CDMO organizations for enterprise-grade documentation automation.
The offering spans document generation aligned to templates and global guidelines, an AI assistant for data work and gap analyses, workflow builder agents, searchable datasets, and technical translation. Outputs link to source data with verification and traceability, and the company highlights security controls including SOC 2 Type II and HIPAA alongside enterprise deployment options.
Bluenote announced general availability of its Regulatory AI Platform for drug and device submissions. The release targets life sciences teams preparing filings for health authorities.
The platform covers authoring, health authority query responses, quality control, and pre-filing risk assessment with source traceability. Each output links to its source data for verification and compliance review.
Bluenote serves life sciences organizations where regulatory submissions, clinical reports and quality validations consume large amounts of researcher time. Demand centers on faster documentation throughput without compromising accuracy, traceability and compliance across nonclinical, clinical, CMC, regulatory and quality functions.
Adoption is evidenced by deployments at customers such as Guardant Health and Eledon Pharmaceuticals, plus a strategic CRO partnership with CMIC announced in March 2026. Reported outcomes cited in ecosystem coverage include faster protocol analysis, accelerated document production, and efficiency gains in specialized quality workflows.